Cure SMA Clinical Care Session 2021 Virtual Conference
TARGET AUDIENCE
This activity is intended for health care providers who diagnose and care for people affected by SMA, including physicians, nurse practitioners, physician assistants and nurses, pediatric and adult specialists including neurologists, pulmonologists, rehabilitation medicine, genetics, orthopedic surgery, palliative care, physical and occupational therapists, speech and language pathologists, pharmacists, nutritionists, genetic counselors, social workers, respiratory therapists, and trainees in the above disciplines.
ACTIVITY OBJECTIVES
The learning objectives for this activity are:
- Demonstrate knowledge of multidisciplinary team roles and responsibilities in care management to optimize SMA outcomes
- Describe the existing and evolving treatment options for patients with SMA
- Describe the impact of new treatments on the SMA phenotype
- Analyze the treatment options for management of infants with SMA identified by SMA newborn screening
- Demonstrate knowledge risk for mental health complications of SMA
- Describe the application of mental health screening tools for SMA outpatient use
ELEMENTS OF COMPETENCE
This activity has been designed to change learner competence and performance and focuses on the American Board of Medical Specialties areas of patient care and procedural skills, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, professionalism, and systems-based practice. This activity also focuses on the interprofessional competencies of values/ethics for interprofessional practice, interprofessional communication, and teams/teamwork.
11:00 AM | Welcome and CMO Update |
11:15 AM | Cure SMA Community Database Outcomes |
11:30 AM | Special Session: Ethics |
12:30 PM | Abstract Presentation |
12:45 PM | Abstract Presentation |
1:00 PM | Abstract Presentation |
1:15 PM | Abstract Presentation |
1:30 PM | Break |
2:00 PM | Musculoskeletal Panel |
3:00 PM | Mental Health Screening and Management Tools |
4:30 PM | SMA Newborn Screening Panel |
It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers, presenters, and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation. For this accredited continuing education activity all relevant financial relationships have been mitigated and detailed disclosures are listed below.
*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by, or on, patients. The ACCME does not consider providers of clinical services directly to patients to be ineligible companies.
CE INFORMATION FOR THE CLINICAL CARE SESSION ONLY
The University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) and Cure SMA gratefully acknowledge the educational grants provided by Genentech and Novartis Gene Therapies.
NAME |
ROLE(S) |
FINANCIAL RELATIONSHIPS DISCLOSURE | DISCUSSION OF UNLABELED/ UNAPPROVED USES OF DRUGS/DEVICES IN PRESENTATION? |
Kapil Arya, MBBS | Presenter | No relevant relationships with ineligible companies to disclose | No |
Mei Baker, MD | Presenter | No relevant relationships with ineligible companies to disclose | No |
Vanessa Battista, RN, MS | Planner, Presenter | AveXis; Biogen; Novartis; PTC Therapeutics, Inc. (All Contractor) | No |
William Bell, PharmD, MBA | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Lisa Belter, MPH | Presenter | No relevant relationships with ineligible companies to disclose | No |
John Brandsema, MD | Planner, Presenter | Alexion Pharmaceuticals; Biogen; Catabasis; CSL Behring; FibroGen; Novartis; PTC Therapeutics, Inc.; Pfizer; Sarepta Therapeutics, Inc.; Summit, WaVe (All Grant); Audentes; Biogen Idec; Cytokinetics; Genentech; Momenta Pharmaceuticals, Inc.; Novartis Pharma; NS Pharma; PTC Therapeutics, Inc.; Sarepta Therapeutics, Inc.; Scholar Rock; WaVe (All Contractor) | No |
Karlla Brigatti, MS, CGC | Presenter | Biogen, Inc.; Novartis (Grant); Novartis (Contractor) | No |
Jin Yun Chen, MS, CGC | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Thomas Crawford, MD | Planner, Presenter | Biogen, Inc.; Genentech USA, Inc.; Sarepta Therapeutics, Inc.; Scholar Rock (All Contractor) | No |
Arlene D’Silva, PhD | Presenter | No relevant relationships with ineligible companies to disclose | No |
Paul Drake, MD | Presenter | No relevant relationships with ineligible companies to disclose | No |
Bakri Elsheikh, MD | Planner, Presenter | Biogen (Contractor and Grant); Genentech (Contractor) | No |
Albert Freedman, PhD | Planner, Presenter | Genentech; Novartis (Both Contractor) | No |
Melissa Gibbons, MS, CGS | Planner, Presenter | Biogen; Novartis (Both Grant) | No |
Jennifer Hubbell, BS | Presenter | No relevant relationships with ineligible companies to disclose | No |
Becky Hurst-Davis, MS, RD | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Brian Jackson, MD, MA | Presenter | No relevant relationships with ineligible companies to disclose | No |
Chamindra Konersman, MD | Planner | Biogen, Inc.; Novartis Pharma; Sarepta Therapeutics, Inc. (All Contractor) | N/A |
Richard Kravitz, MD | Planner | AveXis; Biogen, Inc.; Santhera (All Contractor) | N/A |
Kristin Krosschell, PT, DPT | Planner | ASPA Therapeutics; Biogen; Genentech; Novartis; (All Contractor); Biogen (Grant) | N/A |
Oren Kupfer, MD | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Cathy Means, MS | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Jacqueline Montes, PT, EdD | Presenter | Biogen, Inc.; F. Hoffmann-LaRoche; Genentech USA, Inc.; Sarepta Therapeutics, Inc.; Scholar Rock (All Contractor) | No |
Meghan Moore, PT, DPT | Presenter | Biogen, Inc.; Genentech (Both Contractor) | No |
Pamela Mosher, MD | Presenter | No relevant relationships with ineligible companies to disclose | No |
Diane Murrell, LCSW | Planner, Presenter | No relevant relationships with ineligible companies to disclose | No |
Leslie Nelson | Planner | Avexis; Biogen, Inc.; F. Hoffmann-La Roche; Genentech; Novartis; Scholar Rock (All Contractor) | N/A |
Julie Parsons, MD | Planner, Moderator | Biogen; Genentech; Novartis; Scholar Rock (All Contractor) | No |
Vamshi Rao, MD | Moderator | Avexis; Biogen; Capricor; Genentech; NSpharma; PTC Therapeutics, Inc.; RegenxBio; Sarepta Therapeutics, Inc.; Scholar Rock; Watermark (All Contractor) | No |
Samuel Rosenfeld, MD | Planner, Presenter | OrthoPediatrics Corp. (Contractor) | No |
Peter Schochet, MD | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Mary Schroth, MD | Planner, Medical Director | Audentes Therapeutics (Contractor) | No |
Marisa Schwab, MD | Presenter | No relevant relationships with ineligible companies to disclose | No |
Edward Smith, MD | Planner | Biogen; Genentech; Novartis (All Contractor) | N/A |
Brian Snyder, MD, PhD | Presenter | Alcyone; OrthoPediatrics Corp. (Both Contractor) | No |
Anne Stratton, MD | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Stacey Tarrant, RD, LDN | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Laura Watne, MD, RD | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Elanda Williams, MA | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Amy Xu, BS | Presenter | No relevant relationships with ineligible companies to disclose | No |
Accreditation Statement
![]() | In support of improving patient care, this activity has been planned and implemented by the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) and Cure SMA. The University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. |
Credit Designation Statements | American Medical Association (AMA)The University of Wisconsin-Madison ICEP designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
American Board of PediatricsSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 5.5 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit. | |
American Board of Internal MedicineSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. | |
American Academy of Physician Assistants (AAPA)The University of Wisconsin-Madison ICEP has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 5.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. | |
| American Nurses Credentialing Center (ANCC)The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 5.5 ANCC contact hours. |
Accreditation Council for Pharmacy Education (ACPE)The University of Wisconsin–Madison ICEP designates this knowledge-based activity for a maximum of 5.5 hours/0.55 CEUs of CPE credit. Credit can be earned by documented attendance and by successfully completing the assessment. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. University Activity Number (UAN) JA0000358-9999-21-100-L01-P, 5.5 hours/0.55 CEUs | |
American Psychological Association (APA)(CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. | |
ASWB Approved Continuing Education (ACE) Social Work CreditAs a Jointly Accredited Organization, the University of Wisconsin–Madison ICEP is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. The University of Wisconsin–Madison ICEP maintains responsibility for this course. Social workers completing this course receive 5.5 live continuing education credits. | |
Wisconsin Physical Therapy Association (WPTA)This activity has been approved by the APTA Wisconsin for 5.00 credits (Approval Number 18257). | |
Wisconsin Occupational Therapy Association (WOTA)This activity has been approved by WOTA for 5 credits. | |
| Continuing Education Units (CEUs)The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for .55 CEUs or 5.5 hours. |
Available Credit
- 5.50 AAPA Category 1 CME
- 5.50 MOC: ABIM Medical Knowledge Points (Part II)
- 5.50 MOC: ABP Lifelong Learning Points (Part II)
- 5.50 ACPE Contact Hours - Pharmacist
- 5.50 AMA PRA Category 1 Credit™
- 5.50 ANCC Contact Hours
- 5.50 APA CE Credits
- 5.00 Physical Therapy Contact Hours
- 5.50 University of Wisconsin–Madison Continuing Education Hours
- 5.50 Approved for AMA PRA Category 1 Credit™